3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
15
Neoplasm Metastasis
7
Lung Neoplasms
5
Neoplasms
3
Adenocarcinoma
3
Recurrence
2
Lymphoma, Large-Cell, Anaplastic
2
Granuloma, Plasma Cell
2
Colorectal Neoplasms
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Relapsed Pediatric Solid Tumor
1
Rare Tumor
1
Neurofibromatosis 2
1
Lymphoma, Follicular
1
Lung Adenocarcinoma Metastatic
1
Glioma
1
Glioblastoma
1
Gallbladder Neoplasms
1
Endometrial Cancer Recurrent
1
Diffuse Intrinsic Pontine Glioma
1
Castration-resistant Prostate Cancer
1
Carcinoma, Squamous Cell
1
Carcinoma, Lobular
1
Breast Neoplasms
1
Advanced Cancers
1
Interventions
Bevacizumab
5
Everolimus
4
Sirolimus
2
Lapatinib
2
vistusertib
1
temsirolimus
1
neratinib
1
icotinib
1
brigatinib
1
Vascular Endothelial Growth Factor A
1
Valproic Acid
1
Sunitinib
1
Immunoglobulin G
1
HDAC-42
1
Exome
1
Endostatins
1
Doxycycline
1
Disulfides
1
Crizotinib
1
Cetuximab
1
Axitinib
1
Aspirin
1
AZD 6244
1
89Zr-bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neurofibromatosis 2
×
Crizotinib
×
Clear all
NCT04283669
2026-03-13
NF110
University of Alabama at Birmingham
Phase 2
Completed
12 enrolled
5 charts